Pharmacotherapeutic management of HIV in transplant patients

References

• May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. Aids. 2007;21:1185–1197.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Harris TG, Rabkin M, El-Sadr WM. Achieving the fourth 90: healthy aging for people living with HIV. Aids. 2018;32:1563–1569.
   PubMed Web of Science ®Google Scholar
• Teeraananchai S, Kerr SJ, Amin J, et al. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18:256–266.
   PubMed Web of Science ®Google Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355.
   PubMed Web of Science ®Google Scholar
• Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–1641.
   PubMed Web of Science ®Google Scholar
• Wright AJ, Gill JS. Kidney transplantation in HIV-infected recipients: encouraging outcomes, but registry data are no longer enough. J Am Soc Nephrol. 2015;26:2070–2071.
   PubMed Web of Science ®Google Scholar
• Kendall CE, Wong J, Taljaard M, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;14:161.
   PubMed Web of Science ®Google Scholar
• Taege AJ. Human immunodeficiency virus organ transplantation. Infect Dis Clin North Am. 2018;32:615–634.
   PubMed Web of Science ®Google Scholar
• Jackson KR, Cameron A. Transplantation of the patient with human immunodeficiency virus. Adv Surg. 2017;51:65–76.
   PubMedGoogle Scholar
• Agüero F, Castel MA, Cocchi S, et al. An update on heart transplantation in human immunodeficiency virus-infected patients. Am J Transplant. 2016 Jan;16(1):21–28.
   PubMed Web of Science ®Google Scholar
• Roland ME, Barin B, Huprikar S, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. Aids. 2016;30:435–444.
   PubMed Web of Science ®Google Scholar
• AIDS-defining Cancer Project Working Group of IeDEA and COHERE in EuroCoord. Non-Hodgkin lymphoma risk in adults living with HIV across five continents. Aids. 2018 Nov 28;32:2777–2786.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the swiss HIV cohort study. Blood. 2009;113:5737–5742.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–762.
   PubMed Web of Science ®Google Scholar
• Barta SK, Samuel MS, Xue X, et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol. 2015;26:958–966.
   PubMed Web of Science ®Google Scholar
• Spagnuolo V, Galli L, Salpietro S, et al. Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer. 2012;130:2990–2996.
   PubMed Web of Science ®Google Scholar
• Alvarnas JC, Zaia JA, Forman SJ, et al. How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation. Blood. 2017;130:1976–1984.
   PubMed Web of Science ®Google Scholar
• Re A, Gini G, Rupolo M, et al. Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. Bone Marrow Transplant. 2018;53:228–230.
   PubMed Web of Science ®Google Scholar
• Ramos EL, Kasiske BL, Alexander SR, et al. The evaluation of candidates for renal transplantation. The current practice of U.S. transplant centers. Transplantation. 1994;57:490–497.
   PubMed Web of Science ®Google Scholar
• Halpern SD, Ubel PA, Caplan AL, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284–287.
   PubMed Web of Science ®Google Scholar
• Kolber MA. HIV solid organ transplantation: looking beyond HOPE. Aids. 2018;32:1733–1736.
   PubMed Web of Science ®Google Scholar
• Miro JM, Agüero F, Duclos-Vallée JC, et al. Infections in solid organ transplant HIV-infected patients. Clin Microbiol Infect. 2014;20(Suppl 7):119–130.
   PubMedGoogle Scholar
• Blumberg EA, Rogers CC. Solid organ transplantation in the HIV-infected patient: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Feb;17:e13499.
   Google Scholar
• Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Organ procurement and transplantation: implementation of the HIV Organ Policy Equity Act. Final Rule Fed Regist. 2015;80:26464–26467.
   PubMedGoogle Scholar
• Van Pilsum Rasmussen SE, Bowring MG, Shaffer AA, et al. Knowledge, attitudes, and planned practice of HIV-positive to HIV-positive transplantation in US transplant centers. Clin Transplant. 2018;32:e13365.
   PubMed Web of Science ®Google Scholar
• Muller E, Barday Z. HIV-positive kidney donor selection for HIV-positive transplant recipients. J Am Soc Nephrol. 2018;29:1090–1095.
   PubMed Web of Science ®Google Scholar
• Botha J, Conradie F, Etheredge H, et al. Living donor liver transplant from an HIV-positive mother to her HIV-negative child: opening up new therapeutic options. Aids. 2018;32:F13–F19.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, González-Scarano F. Living donor liver transplant from an HIV-positive individual to an HIV-negative individual: could this become a new reality? Aids. 2018;32:2423–2424.
   PubMed Web of Science ®Google Scholar
• Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015;60:941–949.
   PubMed Web of Science ®Google Scholar
• Mallipattu SK, Salem F, Wyatt CM, et al. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int. 2014;86:259–265.
   PubMed Web of Science ®Google Scholar
• Bickel M, Marben W, Betz C, et al. End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. HIV Med. 2013;14:127–135.
   PubMed Web of Science ®Google Scholar
• Locke JE, Gustafson S, Mehta S, et al. Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg. 2017;265:604–608.
   PubMed Web of Science ®Google Scholar
• Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004–2014.
   PubMed Web of Science ®Google Scholar
• Locke JE, Mehta S, Reed RD, et al. A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol. 2015;26:2222–2229.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. [cited 2018 Dec 10]. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Primeggia J, Timpone JG, Kumar PN. Pharmacologic issues of antiretroviral agents and immunosuppressive regimens in HIV-infected solid organ transplant recipients. Infect Dis Clin North Am. 2013;27:473–486.
   PubMed Web of Science ®Google Scholar
• van Maarseveen EM, Rogers CC, Trofe-Clark J, et al. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS. 2012;26:568–581.
   PubMed Web of Science ®Google Scholar
• Sawinski D, Tebas P. Kidney transplantation in HIV-infected individuals. UpToDate. Waltham, MA: UpToDate Inc.. [cited 2018 Dec 10]. Available from: http://www.uptodate.com
   Google Scholar
• Canaud G, Dejucq-Rainsford N, Avettand-Fenoël V, et al. The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol. 2014;25:407–419.
   PubMed Web of Science ®Google Scholar
• Soriano V, Barreiro P, Sherman KE. The changing epidemiology of liver disease in HIV patients. AIDS Rev. 2013;15:25–31.
   PubMed Web of Science ®Google Scholar
• Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. Aids. 2011;25:777–786.
   PubMedGoogle Scholar
• Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716–726.
   PubMed Web of Science ®Google Scholar
• Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12:1866–1876.
   PubMed Web of Science ®Google Scholar
• Crespo G, Mariño Z, Navasa M, et al. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142:1373–1383.
   PubMed Web of Science ®Google Scholar
• Manzardo C, Londoño MC, Castells L, et al. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. Am J Transplant. 2018;18:2513–2522.
   PubMed Web of Science ®Google Scholar
• Merchante N, Merino E, López-Aldeguer J, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis. 2013;56:143–150.
   PubMed Web of Science ®Google Scholar
• Puoti M, Rossotti R, Garlaschelli A, et al. Hepatocellular carcinoma in HIV hepatitis C virus. Curr Opin HIV AIDS. 2011;6:534–538.
   PubMed Web of Science ®Google Scholar
• Agüero F, Forner A, Manzardo C, et al. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Hepatology. 2016;63:488–498.
   PubMed Web of Science ®Google Scholar
• Ballocca F, D‘Ascenzo F, Gili S, et al. Cardiovascular disease in patients with HIV. Trends Cardiovasc Med. 2017;27:558–563.
   PubMed Web of Science ®Google Scholar
• Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017;17:551.
   PubMed Web of Science ®Google Scholar
• Chen C, Wen X, Yadav A, et al. Outcomes in human immunodeficiency virus infected recipients of heart transplants. Clin Transplant. 2018;33:e13440.
   PubMedGoogle Scholar
• Madan S, Patel SR, Saeed O, et al. Outcomes of heart transplantation in patients with human immunodeficiency virus. Am J Transplant. 2019;00:1–7.
   Google Scholar
• Agüero F, Castel MA, Cocchi S, et al. An update on heart transplantation in human immunodeficiency virus-infected patients. Am J Transplant. 2016;16:21–28.
   PubMed Web of Science ®Google Scholar
• van Sandwijk MS, Bemelman FJ, Ten Berge IJ. Immunosuppressive drugs after solid organ transplantation. Neth J Med. 2013;71:281–289.
   PubMed Web of Science ®Google Scholar
• Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. World J Hepatol. 2015;7:1355–1368.
   PubMed Web of Science ®Google Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387–1394.
   PubMed Web of Science ®Google Scholar
• Szczech LA, Feldman HI. Effect of anti-lymphocyte antibody induction therapy on renal allograft survival. Transplant Proc. 1999;31(3B Suppl):9S–11S.
   PubMed Web of Science ®Google Scholar
• Bunn D, Lea CK, Bevan DJ, et al. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol. 1996;45:29–32.
   PubMed Web of Science ®Google Scholar
• Müller TF, Grebe SO, Neumann MC, et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation. 1997;64:1432–1437.
   PubMed Web of Science ®Google Scholar
• Longuet H, Sautenet B, Gatault P, et al. Risk factors for impaired CD4+ T-cell reconstitution following rabbit antithymocyte globulin treatment in kidney transplantation. Transpl Int. 2014;27:271–279.
   PubMed Web of Science ®Google Scholar
• Suarez JF, Rosa R, Lorio MA, et al. Pretransplant CD4 count influences immune reconstitution and risk of infectious complications in human immunodeficiency virus-infected kidney allograft recipients. Am J Transplant. 2016;16:2463–2472.
   PubMed Web of Science ®Google Scholar
• Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int. 2006;19:705–714.
   PubMed Web of Science ®Google Scholar
• Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77:573–579.
   PubMed Web of Science ®Google Scholar
• 3C Study Collaborative Group, Haynes R, Harden P, et al.. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet. 2014;384:1684–1690.
   PubMed Web of Science ®Google Scholar
• Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48:772–786.
   PubMed Web of Science ®Google Scholar
• Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357:695–697.
   PubMed Web of Science ®Google Scholar
• Webster A, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005;4:CD003961
   Google Scholar
• Eugui EM, Almquist SJ, Muller CD, et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991;33:161–173.
   PubMed Web of Science ®Google Scholar
• Guba M, Graeb C, Jauch KW, et al. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004;77:1777–1782.
   PubMed Web of Science ®Google Scholar
• Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69:2227–2243.
   PubMed Web of Science ®Google Scholar
• Kumar D, LeCorchick S, Gupta G. Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants. Front Med (Lausanne). 2017;4:60.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333–343.
   PubMed Web of Science ®Google Scholar
• Gupta G, Womer KL. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation. Drug Des Devel Ther. 2010;4:375–382.
   PubMed Web of Science ®Google Scholar
• Nulojix. Summary of product characteristics. [assessed 2019 Apr 12]. Available from: https://www.ema.europa.eu/en/documents/product-information/nulojix-epar-product-information_en.pdf
   Google Scholar
• Camargo JF, Chin-Beckford N. Antiretroviral therapy combo pills in HIV+ kidney transplant recipients: first do no harm. Ann Pharmacother. 2017;51:520–521.
   PubMed Web of Science ®Google Scholar
• Moore K, Magee M, Gunshenan M et al. Impact of mild, moderate, and severe renal impairment and hemodialysis on temsavir pharmacokinetics following oral administration of fostemsavir, an attachment inhibitor for heavily treatment experienced HIV-1 infected patients. poster 261. HIV Glasgow 2018, cited 2018 Oct 28–31, Glasgow, UK
   Google Scholar
• Azar MM, Malinis MF, Moss J, et al. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. Int J STD AIDS. 2017;28:447–458.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3:e23–e32.
   PubMed Web of Science ®Google Scholar
• Rosa R, Suarez JF, Lorio MA, et al. Impact of antiretroviral therapy on clinical outcomes in HIV + kidney transplant recipients: review of 58 cases. F1000Res. 2016;5:2893.
   PubMedGoogle Scholar
• Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS. 2016;11:326–332.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society Guidelines. European AIDS clinical society; 2018 ( October). [cited 2018 Dec 10]. Available from: http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf
   Google Scholar
• Dorjee K, Choden T, Baxi SM, et al. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents. 2018;52:541–553.
   PubMed Web of Science ®Google Scholar
• Raffi F, Orkin C, Clarke A, et al. Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75:226–231.
   PubMed Web of Science ®Google Scholar
• Vemlidy, Summary of product characteristics. [cited 2018 Dec 10]. Available from: https://www.ema.europa.eu/documents/product-information/vemlidy-epar-product-information_en.pdf
   Google Scholar
• Podany AT, Scarsi KK, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clin Pharmacokinet. 2017;56:25–40.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Puoti M, Sollima S, et al. Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy? J Antimicrob Chemother. 2016;71:1341–1345.
   PubMed Web of Science ®Google Scholar
• Blanco JL, Whitlock G, Milinkovic A, et al. HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opin Pharmacother. 2015;16:1313–1324.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700–708.
   PubMed Web of Science ®Google Scholar
• Spagnuolo V, Castagna A, Lazzarin A. Bictegravir. Curr Opin HIV AIDS. 2018;13:326–333.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Elvitegravir: a review of its use in adults with HIV-1 infection. Drugs. 2014;74:687–697.
   PubMed Web of Science ®Google Scholar
• Tseng A, Hughes CA, Wu J, et al. Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences. Ann Pharmacother. 2017;51:1008–1022.
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Perry CM. Lopinavir/ritonavir: a review of its use in the management of HIV-1 infection. Drugs. 2010;70:1885–1915.
   PubMed Web of Science ®Google Scholar
• Antunes F. Atazanavir sulfate + cobicistat for the treatment of HIV infection. Expert Rev Anti Infect Ther. 2017;15:569–576.
   PubMed Web of Science ®Google Scholar
• Spagnuolo V, Castagna A, Lazzarin A. Darunavir for the treatment of HIV infection. Expert Opin Pharmacother. 2018;19:1149–1163.
   PubMed Web of Science ®Google Scholar
• Sawinski D, Shelton BA, Mehta S, et al. Impact of protease inhibitor-based anti-retroviral therapy on outcomes for HIV+ kidney transplant recipients. Am J Transplant. 2017;17:3114–3122.
   PubMedGoogle Scholar
• Frassetto L, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7:2816–2820.
   PubMed Web of Science ®Google Scholar
• Muller E, Barday Z, Mendelson M, et al. HIV-positive-to-HIV-positive kidney transplantation–results at 3 to 5 years. N Engl J Med. 2015;372:613–620.
   PubMed Web of Science ®Google Scholar
• Tseng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep. 2012;14:67–82.
   PubMed Web of Science ®Google Scholar
• Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother. 2013;68:250–256.
   PubMed Web of Science ®Google Scholar
• Pifeltro. Full prescribing information. [cited 2018 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
   Google Scholar
• Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018;379:645–654.
   PubMed Web of Science ®Google Scholar
• Cahn P, Fink V, Patterson P, et al. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13:341–345.
   PubMed Web of Science ®Google Scholar
• Aronsohn A. Timing is everything: managing hepatitis C virus in liver transplant candidates. Transplantation. 2017;101:898–899.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.
   Google Scholar
• Verna EC, Brown RS Hepatitis C virus infection in liver transplant candidates and recipients. UpToDate. Waltham, MA:UpToDate Inc.; [cited 2019 Apr 10]. Available from: http://www.uptodate.com
   Google Scholar
• Jadoul M, Berenguer MC, Doss W, et al. Executive summary of the 2018 KDIGO hepatitis C in CKD guideline: welcoming advances in evaluation and management. Kidney Int. 2018;94:663–673.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Treatment regimens for latent TB infection. [cited 2018 Dec 16]. Available from: https://www.cdc.gov/tb/topic/treatment/ltbi.htm
   Google Scholar
• Subramanian A Tuberculosis in solid organ candidates and recipients. UpToDate. Waltham, MA:UpToDate Inc.; [cited 2019 Apr 10]. Available from: http://www.uptodate.com
   Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2013;2014(58):309–318.
   Google Scholar
• Kucirka LM, Durand CM, Bae S, et al. Induction immunosuppression and clinical outcomes in kidney transplant recipients infected with human immunodeficiency virus. Am J Transplant. 2016;16:2368–2376.
   PubMedGoogle Scholar
• Locke JE, James NT, Mannon RB, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation. 2014 Feb 27;97(4):446–450.
   PubMed Web of Science ®Google Scholar
• Balsalobre P, Díez-Martín JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009;27:2192–2198.
   PubMed Web of Science ®Google Scholar
• Alvarnas JC, Le Rademacher J, Wang Y, et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016;128:1050–1058.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105:874–878.
   PubMed Web of Science ®Google Scholar
• Gupta V, Tomblyn M, Pedersen TL, et al. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009 Jul;15(7):864–871.
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR. Hematopoietic stem cell transplantation for HIV cure. J Clin Invest. 2016;126:432–437.
   PubMed Web of Science ®Google Scholar
• Kwon M, Bailén R, Balsalobre P, et al. Allogeneic stem cell transplantation in HIV-1 infected patients with high-risk hematological disorders. Aids. 2019. [Epub ahead of print]
   PubMedGoogle Scholar
• Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med. 2009;360:692–698.
   PubMed Web of Science ®Google Scholar
• Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–377.
   PubMed Web of Science ®Google Scholar
• Allers K, Hütter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2011;117:2791–2799.
   PubMed Web of Science ®Google Scholar
• Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 2013;9:e1003347.
   PubMed Web of Science ®Google Scholar
• Hütter G. More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. N Engl J Med. 2014;371:2437–2438.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Salgado M, Sánchez-Ortega I, et al. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. Lancet HIV. 2015;2:e236–e242.
   PubMed Web of Science ®Google Scholar
• Henrich TJ, Hanhauser E, Marty FM et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014;161:319–327.
   Google Scholar
• Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019;568:244–248.
   PubMed Web of Science ®Google Scholar
• Razonable RR. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation. Curr Opin Infect Dis. 2018;31:286–291.
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–1238.
   PubMed Web of Science ®Google Scholar
• Prevymis. Summary of product characteristics. [cited 2019 Apr 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/prevymis-epar-product-information_en.pdf
   Google Scholar
• Lauterio A, Moioli MC, Di Sandro S, et al. HIV-positive to HIV-positive liver transplantation: to be continued. J Hepatol. 2019;70:788–789.
   PubMed Web of Science ®Google Scholar
• Blumberg EA, Rogers CC. AST infectious diseases community of practice. Human immunodeficiency virus in solid organ transplantation. Am J Transplant. 2013;Suppl 4:169–178.
   Google Scholar
• Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant. 2016;22:717–722.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–733.
   PubMed Web of Science ®Google Scholar
• Hasson H, Merli M, Messina E, et al. Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. J Hepatol. 2017;67:415–417.
   PubMed Web of Science ®Google Scholar